Black Diamond Therapeutics, Inc. (BDTX) Stock

Black Diamond Therapeutics, Inc. (BDTX) is a Healthcare stock trading at $2.20 (as of 2026-08-21), with a market capitalization of $126.40M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Black Diamond Therapeutics, Inc. is a biotechnology company that discovers, develops, and commercializes medicines targeting genetically defined tumors. Its pipeline includes small-molecule inhibitors for specific oncogenic EGFR/HER2 and BRAF alterations, including brain-penetrant candidates, which are intended for use in patients with these tumor-driving mutations.

Understand Black Diamond Therapeutics, Inc.: how it makes money

Black Diamond Therapeutics develops and commercializes medicines for genetically defined tumors, and it makes money through licensing arrangements (license revenue).

The current profit model is driven primarily by License Revenue, so financial results depend on licensing income while the underlying precision oncology programs (including CNS-targeted EGFR mutation inhibitors) work toward clinical and commercial milestones.

Revenue by segment (latest quarter)
License$0.1B
Other$0.0B

Business quality (Mixed): Revenue is dominated by licensing in the latest quarter, while key value creation hinges on trial evidence for targeted oncology therapies (including brain penetration) and safety, as reflected by high rates of serious adverse events in the provided metrics.

Bull case

  • Strong efficacy signals in the CNS: Central Nervous System Objective Response Rate is 86.0% in the provided metrics.
  • Durable-looking disease control: Median Progression-Free Survival is 15.2 (provided metric), and Disease Control Rate is 91.0% (Solid Tumors version 1.1).
  • Licensing revenue contributes to near-term funding: License Revenue is 0.07 USD_B in the quarter ended 2025-03-31.

Bear case

  • High sensitivity to licensing mix: Only License Revenue is explicitly identified as a revenue component, so the business may be exposed if licensing terms change.
  • Safety risk remains material: Rate of Treatment-Related Adverse Events Greater Than Grade 3 is 28.0% (provided metric).
  • Clinical outcomes may be hard to translate: Multiple trial response and survival metrics are provided, but longer-term benefit and broader patient impact are not established in the provided facts.
Valuation — source: SEC EDGAR (first-party)
Price$2.20
Market Cap$126.40M
Price / Book1.32
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$70.00M
Net Margin32.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.34 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderT. Rowe Price Investment Management, Inc. ($22.50M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMark A. Velleca
Employees24
CountryUS
IPO Date2020-01-31

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Invivyd, Inc. (IVVD)
  • LENZ Therapeutics, Inc. (LENZ)
  • TScan Therapeutics, Inc. (TCRX)
  • Kalaris Therapeutics Inc (KLRS)
  • Pelthos Therapeutics Inc. (PTHS)
  • Atara Biotherapeutics, Inc. (ATRA)
  • Cognition Therapeutics, Inc. (CGTX)
  • Outlook Therapeutics, Inc. (OTLK)
BDTX earnings history · BDTX institutional & insider holders · BDTX KPIs & operating metrics · BDTX financials · BDTX investor presentations & press releases · BDTX SEC filings · BDTX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.